Five things plan sponsors need to know about specialty drug spend and trend



Tracy Spencer
Sharon Phares, PhD, MPH
September 20, 2021

 

1.  Specialty Trend Slowing
Would you be surprised to learn specialty drug trend slowed in 2020 compared to recent years?  Unfortunately, we know that the pandemic likely impacted trend because people delayed preventative screenings and starting treatment. For instance, preventative screenings for breast cancer were down 96.6% in April 2020 compared to April 2019.

 


 

2.  Specialty Utilization Rising
Specialty drug utilization rates continue to rise. Patients using specialty medications are using more of them (8.3% increase in claims perutilizer), even though the percent of all members using specialty medications remained flat.

 


 

3.  Market Traction for Biosimilars
Biosimilars are driving savings in two ways. First, they cost less than innovator brands. Secondly, they put price pressure on the innovators.

For example, from January 2019 to December 2020, Remicade ASP (Average Sales Price) reduced from $75 per unit to $45 per unit.  Unfortunately, the market has not fully recognized the savings opportunities presented by biosimilars. There continue to be interchangeability restrictions that hinder broader adoption.

 

 


 

4.  Savings Opportunities
Specialty cost saving opportunities remain in three primary categories:

  1. Lower cost sites of care
  2. Review and management of outlier claims
  3. Utilization management to ensure clinical appropriateness

The savings can be significant. For example, shifting just two specialty medications from outpatient hospitals to home infusion or physician offices can save the average plan between $77,811 and $94,403.

 


 

5.  Rare Disease Pipeline
New therapies for rare diseases such as cystic fibrosis (CF) generate headlines. The special “Investing in Hope” section of PSG’s State of Specialty Spend and Trend Report (page 35) details how Trikafta is changing the lives of those living with CF. Plan sponsors welcome the positive benefits to their populations. Across the PSG book of business, 74% of members experienced decreased medical costs after starting treatment with Trikafta.

 

 

 

These innovative therapies provide hope for people living with life-threatening conditions. However, only 5% of rare diseases have treatments available, and these treatments come with incredibly high price tags. Yet when available, the improvement of quality of life and added years of life are remarkable.

 

 

 


 

Download the complete report to learn more

 



Tracy Spencer is a recognized industry leader with more than two decades of pharmacy and medical benefits experience developing and expanding relationships with C-suite and executive leadership of numerous Fortune 100 companies.

Sharon Phares, PhD, MPH, is the Senior Vice President of Research for PSG and an Assistant Adjunct Professor of Clinical Pediatrics and Assistant Adjunct Professor of Internal Medicine with Washington University in St. Louis. Prior to joining the PSG, Sharon was Vice President of Research and Analytics at Express Scripts where she led research strategy and execution for one of the largest PBMs in the nation. She has also held leadership roles in health and economic outcomes research, survey design, pilot and program design and evaluation, analytics and research consulting, advanced analytics, and the development of predictive models at Walgreens, LabCorp, and Landacorp. She was an instructor at North Carolina State University and provided evaluation research for various state and local government agencies before joining the private sector.